Fortress Biotech, Inc. (FBIO)

Fortress Biotech (FBIO) demonstrates strong net bullish sentiment driven by rising Q2 2026 revenues to $18.7 million, robust cash reserves of $196.6 million, and positive valuation models indicating upside potential amidst a stable $95 million market cap.